{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:48:14Z","timestamp":1791557294933,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.schres.2014.05.009","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T13:14:27Z","timestamp":1401714867000},"page":"137-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Second-generation antipsychotics and bone turnover in schizophrenia"],"prefix":"10.1016","volume":"157","author":[{"given":"Kyoji","family":"Okita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Kanahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomihisa","family":"Niitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2014.05.009_bb0005","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1176\/appi.ajp.160.9.1618","article-title":"Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study","volume":"160","author":"Abraham","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.05.009_bb0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000117734","article-title":"Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy","volume":"6","author":"Baastrup","year":"1980","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2014.05.009_bb0015","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v64n0704","article-title":"Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients","volume":"64","author":"Becker","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.05.009_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1743-7075-2-9","article-title":"Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study","volume":"2","author":"Castro","year":"2005","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.schres.2014.05.009_bb0025","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1007\/s11999-011-1780-7","article-title":"Gender differences in osteoporosis and fractures","volume":"469","author":"Cawthon","year":"2011","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.schres.2014.05.009_bb0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00198-009-0838-9","article-title":"Bone turnover markers: understanding their value in clinical trials and clinical practice","volume":"20","author":"Civitelli","year":"2009","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.schres.2014.05.009_bb0035","series-title":"Baillieres Best Pract Res Clin Endocrinol Metab","article-title":"Fractures in the elderly: epidemiology and demography","author":"De Laet","year":"2000"},{"key":"10.1016\/j.schres.2014.05.009_bb0040","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature03398","article-title":"Leptin regulation of bone resorption by the sympathetic nervous system and CART","volume":"434","author":"Elefteriou","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.schres.2014.05.009_bb0045","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.schres.2014.05.009_bb0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/PL00004148","article-title":"World-wide projections for hip fracture","volume":"7","author":"Gullberg","year":"1997","journal-title":"Osteoporos. Int."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2014.05.009_bb0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2014.05.009_bb0060","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00006842-199509000-00011","article-title":"Decreased bone mineral density in medicated psychiatric patients","volume":"57","author":"Halbreich","year":"1995","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.schres.2014.05.009_bb0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00223-001-2122-7","article-title":"Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density","volume":"71","author":"Halleen","year":"2002","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.schres.2014.05.009_bb0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1176\/appi.ajp.162.1.162","article-title":"Osteoporosis in patients with schizophrenia","volume":"162","author":"Hummer","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2014.05.009_bb0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medication or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoendocrinology"},{"key":"10.1016\/j.schres.2014.05.009_bb0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4088\/JCP.v69n0307","article-title":"Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo\u2013pituitary\u2013gonadal axis and reduces bone mineral density in male patients with schizophrenia","volume":"69","author":"Kishimoto","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2014.05.009_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2014.05.009_bb0090","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ocl.2006.09.002","article-title":"Osteoporosis: differences and similarities in male and female patients","volume":"37","author":"Lane","year":"2006","journal-title":"Orthop. Clin. N. Am."},{"key":"10.1016\/j.schres.2014.05.009_bb0095","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4306\/pi.2010.7.4.278","article-title":"Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study","volume":"7","author":"Lee","year":"2010","journal-title":"Psychiatr. Investig."},{"key":"10.1016\/j.schres.2014.05.009_bb0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/rp.57.1.385","article-title":"Sex steroids and bone","volume":"57","author":"Manolagas","year":"2002","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.schres.2014.05.009_bb0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2007.01.013","article-title":"Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables","volume":"93","author":"Meaney","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2014.05.009_bb0110","series-title":"Endocrine Physiology","author":"Molina","year":"2009"},{"key":"10.1016\/j.schres.2014.05.009_bb0115","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.schres.2014.05.009_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","article-title":"Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?","volume":"25","author":"O'Keane","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2014.05.009_bb0125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0269881107088439","article-title":"Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia","volume":"22","author":"O'Keane","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2014.05.009_bb0130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.bone.2004.04.020","article-title":"The association of bone metabolism with bone mineral density, serum sex hormone concentrations, and regular exercise in middle-aged men","volume":"35","author":"Remes","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.schres.2014.05.009_bb0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2474-11-35","article-title":"Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients","volume":"11","author":"Renn","year":"2010","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.schres.2014.05.009_bb0140","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/hup.1250","article-title":"No association between bone mass and prolactin levels among patients with schizophrenia","volume":"26","author":"Sugawara","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2014.05.009_bb0145","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cell.2009.06.051","article-title":"A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure","volume":"138","author":"Yadav","year":"2009","journal-title":"Cell"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414002394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996414002394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T14:23:37Z","timestamp":1538576617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996414002394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":29,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0920996414002394"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2014.05.009","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-generation antipsychotics and bone turnover in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2014.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}